Phase 4 N=7 Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb
Dupuytren's Contracture
Primary: Number Patients Obtaining Clinical Improvement (>50% Reduction in Contracture) — 5; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,088 Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 34.66; 30.29 Months
Phase 4 N=76 The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
Episodic Migraine
Primary: Change in Headache Intensity — -47.6; -20.7 percent change
Phase 2 N=9 Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells
Multiple Sclerosis, Relapsing-Remitting
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Phase 2 N=75 Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Diabetes Mellitus, Type 1
Primary: Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo — -3.56; 72.45; 103.33; 101.79 g/24h…
N/A N=101 Effect of Exercise on Gait and Balance in Peripheral Neuropathy
Diabetic Neuropathies · Peripheral Nerve Diseases · Peripheral Nervous System Diseases
Primary: Gait and Balance Measures — 51.3; 51.2; 52.3 units on a scale
N/A N=191 A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTSD
Posttraumatic Stress Disorder
Primary: Change From Baseline in Clinician Administered PTSD Scale — -22.4; -15.9 units on a scale — p=0.5
Phase 1 N=24 Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State
Malaria
Primary: OZ439 Cmax — 1540; 1360; 1610 ng/mL
N/A N=181 Progressive Intervention Program for Tinnitus Management
Hearing Loss · Tinnitus
Primary: THI (Tinnitus Handicap Inventory) — 37.0; 43.0; 33.0; 40.0 scores on a scale
N/A N=20 Stability of Motor Output in Aging Adults
Swallowing
Primary: Mean Motor Evoked Potential Amplitude for Submental Cortical Representation
Phase 3 N=189 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -36.3 percentage of curvature change
Phase 3 N=417 Study of AA4500 in the Treatment of Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -37.6; -21.3 percentage of curvature change — p=0.0005
Phase 3 N=218 Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim
Chemotherapy Associated Neutropenia · Breast Cancer
Primary: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy — 1.17; 1.2 Days
N/A N=50 The Safety Evaluation of Silver Alginate (Algidex™) Dressing in Very Low Birth Weight (VLBW) Infants
Prematurity · Very Low Birth Weight
Primary: Serum Silver Concentration at 1 Day — 7.6; 0.22 ng ml -1
Phase 3 N=45 RELOVAIR® Lung Deflation Study
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVI) at the End of the Overall Treatment Period — -0.47; 5.35 Milliliter per meter square…